10-Q quarterly report · filed Nov 4, 2026

Evolus, Inc. (EOLS) Q3 2026 10-Q Quarterly Report

Short answer

Evolus, Inc. (EOLS) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $78M (up 13.0% year over year) with net income of −$13M.

Q3 2026 key financials · XBRL

Revenue
$78M
+13.0% YoY · −7.3% QoQ
Net income
−$13M
+20.5% YoY · −55.4% QoQ
Operating margin
-10.8%
Gross margin
65.0%
EPS (diluted)
−$0.19
+20.8% YoY · −46.2% QoQ

Source: XBRL data from the Evolus, Inc. (EOLS) Q3 2026 10-Q on SEC EDGAR. USD.

Evolus, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $78.0M, up 13.0% from $69.0M, driven by higher Jeuveau and Evolysse sales
  • Gross margin 65.0% vs 66.5% YoY, operating loss $8.4M vs $11.5M
  • One reportable segment, Jeuveau and Evolysse; both products cited as revenue-growth drivers
  • Cash $41.7M, operating cash use $15.5M through nine months vs $55.1M YoY
  • Outlook: growth dependent on Evolysse launches and U.S. approvals, with tariff and discretionary-spending headwinds

Risk Factors

  • New tariff risk triggered by 2026 Section 232 action: South Korean Jeuveau imports currently face 15% tariffs, with potential rates up to 100%
  • Regulatory risk from Section 232 medical-device investigation: future tariffs, quotas, or import restrictions could affect France-sourced Evolysse
  • Competitive risk: AbbVie and Galderma retain larger market shares, sales forces, portfolios, and discounting capacity
  • Financial risk: $31.2 million nine-month net loss and $692.3 million accumulated deficit increase reliance on future financing
  • Supply risk: sole reliance on Daewoong and Symatese leaves Jeuveau and Evolysse vulnerable to manufacturing disruptions

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Evolus, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.